Harbin Veterinary Research Institute, CAAS-Michigan State University Joint Laboratory of Innate Immunity, State Key Laboratory of Veterinary Biotechnology, Chinese Academy of Agricultural Sciences, Harbin, China.
Harbin Veterinary Research Institute, CAAS-Michigan State University Joint Laboratory of Innate Immunity, State Key Laboratory of Veterinary Biotechnology, Chinese Academy of Agricultural Sciences, Harbin, China
J Virol. 2019 Jan 4;93(2). doi: 10.1128/JVI.01651-18. Print 2019 Jan 15.
Glycosylated Gag (glycoGag) is an accessory protein expressed by most gammaretroviruses, including murine leukemia virus (MLV). MLV glycoGag not only enhances MLV replication and disease progression but also increases human immunodeficiency virus type 1 (HIV-1) infectivity as Nef does. Recently, SERINC5 (Ser5) was identified as the target for Nef, and the glycoGag Nef-like activity has been attributed to the Ser5 antagonism. Here, we investigated how glycoGag antagonizes Ser5 using MLV glycoMA and murine Ser5 proteins. We confirm previous observations that glycoMA relocalizes Ser5 from plasma membrane to perinuclear punctated compartments and the important role of its YXXL motif in this process. We find that glycoMA decreases Ser5 expression at steady-state levels and identify two other glycoGag crucial residues, P31 and R63, for the Ser5 downregulation. The glycoMA and Ser5 interaction is detected in live cells using a bimolecular fluorescence complementation assay. Ser5 is internalized via receptor-mediated endocytosis and relocalized to Rab5 early, Rab7 late, and Rab11 recycling endosomes by glycoMA. Although glycoMA is not polyubiquitinated, the Ser5 downregulation requires Ser5 polyubiquitination via the K48- and K63-linkage, resulting in Ser5 destruction in lysosomes. Although P31, Y36, L39, and R63 are not required for glycoMA interaction with Ser5, they are required for Ser5 relocalization to lysosomes for destruction. In addition, although murine Ser1, Ser2, and Ser3 exhibit very poor antiviral activity, they are also targeted by glycoMA for lysosomal destruction. We conclude that glycoGag has a broad activity to downregulate SERINC proteins via the cellular endosome/lysosome pathway, which promotes viral replication. MLV glycoGag not only enhances MLV replication but also increases HIV-1 infectivity similarly as Nef. Recent studies have discovered that both glycoGag and Nef antagonize a novel host restriction factor Ser5 and promote viral replication. Compared to Nef, the glycoGag antagonism of Ser5 is still poorly understood. MLV glycoGag is a transmembrane version of the structural Gag protein with an extra 88-amino-acid leader region that determines its activity. We now show that glycoGag interacts with Ser5 in live cells and internalizes Ser5 via receptor-mediated endocytosis. Ser5 is polyubiquitinated and relocalized to endosomes and lysosomes for massive destruction. In addition to the previously identified tyrosine-based sorting signal, we find two more important residues for Ser5 relocalization and downregulation. We also find that the Ser5 sensitivity to glycoGag is conserved in the SERINC family. Together, our findings highlight the important role of endosome/lysosome pathway in the enhancement of viral replication by viral proteins.
糖基化 Gag(glycoGag)是大多数γ逆转录病毒(包括鼠白血病病毒[MLV])表达的一种辅助蛋白。MLV glycoGag 不仅增强 MLV 的复制和疾病进展,还像 Nef 一样增加人类免疫缺陷病毒 1(HIV-1)的感染性。最近,SERINC5(Ser5)被鉴定为 Nef 的靶标,glycoGag 的 Nef 样活性归因于 Ser5 的拮抗作用。在这里,我们使用 MLV glycoMA 和鼠 Ser5 蛋白研究了 glycoGag 如何拮抗 Ser5。我们证实了以前的观察结果,即 glycoMA 将 Ser5 从质膜重新定位到核周点状区室,并且其 YXXL 基序在该过程中起着重要作用。我们发现 glycoMA 在稳定状态水平下调 Ser5 的表达,并确定了另外两个 glycoGag 关键残基 P31 和 R63,用于 Ser5 下调。使用双分子荧光互补测定法在活细胞中检测到 glycoMA 和 Ser5 之间的相互作用。Ser5 通过受体介导的内吞作用内化,并通过 glycoMA 重新定位到 Rab5 早期、Rab7 晚期和 Rab11 再循环内体。尽管 glycoMA 不被多泛素化,但 Ser5 的下调需要 Ser5 通过 K48 和 K63 链接的多泛素化,导致 Ser5 在溶酶体中被破坏。尽管 P31、Y36、L39 和 R63 对于 glycoMA 与 Ser5 的相互作用不是必需的,但它们对于 Ser5 重新定位到溶酶体以进行破坏是必需的。此外,尽管鼠 Ser1、Ser2 和 Ser3 表现出非常差的抗病毒活性,但它们也被 glycoMA 靶向用于溶酶体破坏。我们得出结论,glycoGag 通过细胞内体/溶酶体途径具有下调 SERINC 蛋白的广泛活性,从而促进病毒复制。MLV glycoGag 不仅增强 MLV 的复制,还像 Nef 一样增加 HIV-1 的感染性。最近的研究发现,glycoGag 和 Nef 都拮抗一种新的宿主限制因子 Ser5 并促进病毒复制。与 Nef 相比,glycoGag 对 Ser5 的拮抗作用仍知之甚少。MLV glycoGag 是结构 Gag 蛋白的跨膜版本,具有额外的 88 个氨基酸的前导区,决定其活性。我们现在表明 glycoGag 在活细胞中与 Ser5 相互作用,并通过受体介导的内吞作用内化 Ser5。Ser5 被多泛素化并重新定位到内体和溶酶体中进行大量破坏。除了先前鉴定的基于酪氨酸的分拣信号外,我们还发现了另外两个对 Ser5 重新定位和下调很重要的残基。我们还发现 Ser5 对 glycoGag 的敏感性在 SERINC 家族中是保守的。总之,我们的研究结果强调了内体/溶酶体途径在病毒蛋白增强病毒复制中的重要作用。